📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding HIMS

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Jim Simons Renaissance Technologies LLC	2.12M	$44.0M	0.07%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management used phrases like 'working at scale', 'remarkable success', and 'strong results' with specific figures (73% revenue growth, 2.4M subs, 15%+ EBITDA margin). They proactively addressed headwinds (GLP-1 offboarding, sexual health rotation) and framed them as strategic transitions, not failures.

Q3 2025

Confident Specific

Management consistently used assertive language such as 'strong step forward', 'strategy is working', 'never been more excited', and provided specific numerical guidance and milestones (e.g., revenue targets, subscriber growth, margin percentages). The tone was forward-leaning with detailed expansion plans.

Q4 2025

Mixed

Management projects confidence with phrases like 'tremendous progress' and 'our conviction underpins our confidence', but also hedges with 'we expect to encounter challenges' and issues wide guidance ranges, indicating a balance between optimism and caution.

Q1 2026 latest

Confident Specific

Management used specific data points ('125,000 shipments', 'north of 100,000 new subscribers per month'), positive language ('strong, meaningful start', 'accelerating growth'), and repeatedly reinforced long-term targets ($6.5B revenue, $1.3B EBITDA) to convey conviction in the strategic pivot.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is stronger after this call. Management demonstrated early execution on the weight loss pivot, with specific metrics (125,000 Wegovy shipments, 100k+ monthly subscriber adds) that surpassed prior peak demand periods. The expansion into new specialties (testosterone, menopause, labs) and AI-driven platform improvements suggest a durable competitive moat. However, near-term margin compression from one-month shipping cadences and restructuring costs (one-time $33M) creates GAAP volatility. Key watch items for next quarter: gross margin trajectory, retention of branded weight loss subscribers, progress on peptide regulatory pathway (July 2026), and any updates on Eucalyptus closing. The reiterated 2030 targets ($6.5B revenue, $1.3B EBITDA) provide a long-term anchor, but investors should monitor whether the acceleration in top-line growth translates into sequential improvement in adjusted EBITDA dollars as guided for H2.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Hims & Hers Q1 2026: $608M revenue, 2.6M subscribers, strategic pivot to branded GLP-1s.

Revenue & Profitability

Revenue in Q1 2026 was $608 million, up 4% year-over-year. Adjusted EBITDA was $44 million (7% margin). GAAP net loss was $92 million, impacted by $33 million in restructuring costs from the weight loss pivot. Free cash flow was $53 million. The full-year revenue guidance was raised to $2.8-$3.0 billion, with adjusted EBITDA expected between $275 million and $350 million.

Outlook

Management sees strong demand for weight loss solutions, with over 100 million U.S. adults struggling. The shift to branded products has driven record subscriber additions. They believe the platform is positioned for long-term growth, reaffirming 2030 targets of $6.5 billion revenue and $1.3 billion adjusted EBITDA, though near-term financial volatility is expected.

Growth Drivers

Key growth levers include the strategic pivot to branded GLP-1s (125,000+ Wegovy shipments in six weeks), newer specialties like testosterone, menopause, and labs, and international expansion via the planned acquisition of Eucalyptus. The company is adding over 100,000 new weight loss subscribers per month, with high engagement (90% app download, 3x provider interactions in first month).

Balance Sheet & CapEx

Capital deployment focuses on technology (AI team now nearly 40 members), verticalization (1 million+ sq ft pharmacy facilities, peptide manufacturing), and acquisitions (YourBio for painless blood sampling, Eucalyptus for $240 million). Q1 CapEx included $33 million in restructuring costs for the supply chain pivot. Management expects to leverage technology investments to reduce costs from 2027.

Margins

Gross margins were 65% GAAP (70% adjusted for one-time charges). Marketing efficiency improved 3 points to 36% of revenue. Near-term compression expected as weight loss shifts to one-month shipments. Full-year adjusted EBITDA margin implied at 11% midpoint. Operating leverage in G&A and marketing is expected to drive margin expansion in H2 2026 and into 2027.

Key Risks

Risks flagged include regulatory uncertainty for peptides (FDA reclassification expected July), potential volatility from the strategic pivot, and short-term gross margin compression. Transition period may cause GAAP net income swings; management expects profitability in 2027. M&A integration (Eucalyptus) and international expansion carry execution risks.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-10

Q2 2026 saw 40% revenue growth to $753M, driven by AI-powered care, international expansion, and strong weight loss and testosterone specialties. Adjusted EBITDA reached $60M, with guidance raised for 2026. Gross margin declined due to mix shift, but operational efficiencies and global scale support long-term growth.

Q1 2026 Q1 2026 2026-05-11

Q1 2026 saw 4% revenue growth to $608M and a strategic pivot to branded weight loss products, driving rapid subscriber gains and engagement. Despite a GAAP net loss from restructuring, adjusted EBITDA was $44M, and full-year guidance was raised. Confidence remains high in achieving 2030 targets.

Q4 2025 Q4 2025 2026-02-23

Revenue grew 59% to $2.35B in 2025, with strong subscriber growth and expansion into new specialties and international markets. Adjusted EBITDA rose 80% to $318M, and guidance for 2026 anticipates up to $2.9B in revenue. Majority of revenue and profit comes from non-GLP-1 offerings.

Q3 2025 Q3 2025 2025-11-03

Q3 2025 saw 49% revenue growth and strong subscriber gains, driven by new personalized offerings and international expansion. Investments in technology, partnerships, and verticalization support long-term growth, with 2025 revenue expected to rise nearly 60% year-over-year.

Q2 2025 Q2 2025 2025-08-04

Q2 revenue grew 73% year-over-year to $545M, with over 2.4M subscribers and strong growth in dermatology, weight loss, and daily sexual health. Guidance raised for 2025, with continued investment in technology, AI, and international expansion.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.